Corbus Pharmaceuticals Holdings Company Profile (NASDAQ:CRBP)

About Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings logoCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CRBP
  • CUSIP: N/A
  • Web: www.corbuspharma.com
Capitalization:
  • Market Cap: $321.4 million
  • Outstanding Shares: 50,218,000
Average Prices:
  • 50 Day Moving Avg: $6.35
  • 200 Day Moving Avg: $7.28
  • 52 Week Range: $2.76 - $10.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.81 million
  • Price / Sales: 114.38
  • Book Value: $0.87 per share
  • Price / Book: 7.36
Profitability:
  • EBIDTA: ($24,450,000.00)
  • Net Margins: -874.41%
  • Return on Equity: -117.78%
  • Return on Assets: -88.66%
Debt:
  • Current Ratio: 7.21%
  • Quick Ratio: 7.21%
Misc:
  • Average Volume: 669,246 shs.
  • Beta: 2.53
  • Short Ratio: 10.28
 
Frequently Asked Questions for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

What is Corbus Pharmaceuticals Holdings' stock symbol?

Corbus Pharmaceuticals Holdings trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals Holdings' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Tuesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm earned $1.29 million during the quarter, compared to analyst estimates of $2.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 874.41% and a negative return on equity of 117.78%. View Corbus Pharmaceuticals Holdings' Earnings History.

When will Corbus Pharmaceuticals Holdings make its next earnings announcement?

Corbus Pharmaceuticals Holdings is scheduled to release their next quarterly earnings announcement on Monday, August, 14th 2017. View Earnings Estimates for Corbus Pharmaceuticals Holdings.

Where is Corbus Pharmaceuticals Holdings' stock going? Where will Corbus Pharmaceuticals Holdings' stock price be in 2017?

4 equities research analysts have issued twelve-month price targets for Corbus Pharmaceuticals Holdings' shares. Their predictions range from $12.00 to $27.00. On average, they expect Corbus Pharmaceuticals Holdings' share price to reach $20.50 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals Holdings.

Who are some of Corbus Pharmaceuticals Holdings' key competitors?

Who are Corbus Pharmaceuticals Holdings' key executives?

Corbus Pharmaceuticals Holdings' management team includes the folowing people:

  • Mark A. Tepper Ph.D., President, Chief Scientific Officer
  • Yuval Cohen Ph.D., Chief Executive Officer, Director
  • Sean F. Moran CPA, Chief Financial Officer
  • Barbara White M.D., Chief Medical Officer
  • David P Hochman, Director
  • Avery W. Catlin CPA, Independent Director
  • Renu Gupta M.D., Independent Director
  • Alan F. Holmer J.D., Independent Director

Who owns Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Creative Planning (0.35%), Woodstock Corp (0.11%) and Evanson Asset Management LLC (0.04%). Company insiders that own Corbus Pharmaceuticals Holdings stock include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran, Sumner Burstein and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals Holdings.

Who bought Corbus Pharmaceuticals Holdings stock? Who is buying Corbus Pharmaceuticals Holdings stock?

Corbus Pharmaceuticals Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning and Evanson Asset Management LLC. Company insiders that have bought Corbus Pharmaceuticals Holdings stock in the last two years include Alan F Holmer, Avery W Catlin, Barbara White, David P Hochman, Renu Gupta, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals Holdings.

How do I buy Corbus Pharmaceuticals Holdings stock?

Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals Holdings' stock price today?

One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $6.40.


MarketBeat Community Rating for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.50 (220.31% upside)

Analysts' Ratings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Cantor FitzgeraldSet Price TargetBuy$24.00LowView Rating Details
6/16/2017Noble FinancialReiterated RatingBuyHighView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 -> $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Earnings History by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ CRBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017($0.19)N/AView Earnings Details
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.12)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS

Dividends

Dividend History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 28.06%
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Insider Trades by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.50View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.00View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.60View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.00View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.00View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.00View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.00View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.00View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.00View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.00View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.00View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.00View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.00View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.00View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.00View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.00View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.00View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.00View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.00View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.00View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.00View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.00View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.00View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.00View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.00View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.00View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.00View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Latest Headlines for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)
Source:
DateHeadline
finance.yahoo.com logoHow To Profit From Canada’s $22 Billion Marijuana Boom
finance.yahoo.com - July 19 at 11:41 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - July 17 at 4:04 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 7:33 PM
prnewswire.com logoCannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:37 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. – Value Analysis (NASDAQ:CRBP) : July 11, 2017
finance.yahoo.com - July 11 at 6:37 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bullish Manner : CRBP-US : July 10, 2017
finance.yahoo.com - July 10 at 5:30 PM
americanbankingnews.com logoBidaskClub Upgrades Corbus Pharmaceuticals Holdings, Inc. (CRBP) to "Hold"
www.americanbankingnews.com - July 8 at 8:26 PM
thestreet.com logoCommit To Buy Corbus Pharmaceuticals Holdings At $5, Earn 17.2 ... - TheStreet.com
www.thestreet.com - July 7 at 4:53 AM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index
finance.yahoo.com - June 26 at 5:14 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Expected to Earn FY2018 Earnings of ($0.66) Per Share
www.americanbankingnews.com - June 26 at 10:42 AM
seekingalpha.com logoCorbus Pharmaceuticals Can Hit New Highs By Year's End - Seeking Alpha
seekingalpha.com - June 23 at 10:06 PM
americanbankingnews.com logoNoble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
www.americanbankingnews.com - June 17 at 7:16 AM
streetinsider.com logoCorbus Pharma (CRBP) Announces Data from Phase 2 Study of ... - StreetInsider.com
www.streetinsider.com - June 16 at 4:26 AM
reuters.com logoBRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis
www.reuters.com - June 15 at 6:22 PM
finance.yahoo.com logoCorbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting
finance.yahoo.com - June 15 at 6:22 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : June 14, 2017
finance.yahoo.com - June 14 at 5:23 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 13 at 5:56 PM
finance.yahoo.com logoMarijuana Stocks Be Warned: Nevada's Recreational Weed Law May Have a Big Issue
finance.yahoo.com - June 10 at 4:41 PM
finance.yahoo.com logoCorbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
finance.yahoo.com - June 8 at 5:30 PM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bullish Manner : CRBP-US : June 6, 2017
finance.yahoo.com - June 6 at 4:43 PM
finance.yahoo.com logoCorbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference
finance.yahoo.com - June 1 at 5:05 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:19 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Short Interest Update
www.americanbankingnews.com - May 22 at 2:46 PM
finance.yahoo.com logoTop 4 Marijuana Stocks to Watch for 2017
finance.yahoo.com - May 18 at 4:24 PM
americanbankingnews.com logoNoble Financial Reiterates Buy Rating for Corbus Pharmaceuticals Holdings Inc (CRBP)
www.americanbankingnews.com - May 14 at 8:45 AM
americanbankingnews.com logoInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Purchases 3,400 Shares of Stock
www.americanbankingnews.com - May 12 at 4:46 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) CFO Sean F. Moran Buys 3,300 Shares
www.americanbankingnews.com - May 12 at 4:46 PM
americanbankingnews.com logoInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Buys 2,435 Shares of Stock
www.americanbankingnews.com - May 12 at 10:17 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) CEO Yuval Cohen Purchases 3,250 Shares
www.americanbankingnews.com - May 12 at 10:16 AM
streetinsider.com logoCorbus Pharma (CRBP) Says Last Subject Enrolled in Phase 2 Study of Anabasum - StreetInsider.com
www.streetinsider.com - May 11 at 5:07 PM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:07 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 12:04 AM
finance.yahoo.com logoCorbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 4:41 PM
finance.yahoo.com logoToday's Research Reports on Corbus Pharmaceuticals and Pluristem Therapeutics Post Earnings
finance.yahoo.com - May 10 at 8:10 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings Inc (CRBP) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 11:36 PM
finance.yahoo.com logoCorbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 4:29 PM
marketbeat.com logoCorbus Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 9:22 AM
prnewswire.com logoThe Creation of Jobs in the Legal Cannabis Market
www.prnewswire.com - May 5 at 4:41 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 1:15 AM
finance.yahoo.com logoRead This Before You Buy Biotech Stocks
finance.yahoo.com - May 1 at 8:25 AM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 7:26 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earning Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 5:07 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Given Daily Coverage Optimism Rating of 0.23
www.americanbankingnews.com - April 20 at 4:52 PM
americanbankingnews.com logoCorbus Pharmaceuticals Holdings (CRBP) Earns Media Sentiment Rating of 0.24
www.americanbankingnews.com - April 14 at 9:22 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma - PR Newswire (press release)
www.prnewswire.com - April 12 at 8:18 AM
finance.yahoo.com logoDid Corbus Investors Get Thrown Off by a Red Herring?
finance.yahoo.com - April 10 at 4:20 PM
finance.yahoo.com logoWhat's Next for Corbus Pharmaceuticals After Its Controversial Cystic Fibrosis Results?
finance.yahoo.com - April 8 at 4:23 PM

Social

Chart

Corbus Pharmaceuticals Holdings (CRBP) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff